Cost-utility of adjuvant hormone therapies for breast cancer in post-menopausal women: sequential tamoxifen-exemestane and upfront anastrozole

被引：0

作者：

C. Skedgel

D. Rayson

R. Dewar

T. Younis

机构：

[1] Dalhousie University,Department of Medicine, Centre for Clinical Research

[2] Cancer Care Nova Scotia,undefined

来源：

Breast Cancer Research and Treatment | 2007年 / 101卷

关键词：

Adjuvant hormonal therapy; Anastrozole; Aromatase inhibitors; Breast cancer; Cost-utility analysis; Exemestane; Tamoxifen;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：325 / 333

页数：8

共 50 条

[21] TAMOXIFEN AND PROLACTIN SECRETION IN POST-MENOPAUSAL WOMEN WITH ADVANCED BREAST-CANCER
VANDERGEEST, S
SLUITER, WJ
DOORENBOS, H
REITSMA, WD
NETHERLANDS JOURNAL OF MEDICINE, 1983, 26 (04): : 99 - 103
[22] Tamoxifen and exemestane (E) in combination as neoadjuvant treatment of hormone sensitive post-menopausal breast cancer women:: Clinical efficacy and effects an tumor pathology and immunopathology.
Dalenc, F
Lacroix-Triki, M
Serone-Vivien, S
Ferron, G
Couteau, C
Gladieff, L
Maudelonde, T
Roché, H
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 876S - 876S
[23] THE EFFECT OF TAMOXIFEN ON PLASMA GROWTH-HORMONE AND PROLACTIN IN POST-MENOPAUSAL WOMEN WITH ADVANCED BREAST-CANCER
PATERSON, AG
TURKES, A
GROOM, GV
WEBSTER, DJT
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1983, 19 (07): : 919 - 922
[24] EFFECT OF TAMOXIFEN AND STILBESTROL ON PLASMA-HORMONE LEVELS IN POST-MENOPAUSAL WOMEN WITH ADVANCED BREAST-CANCER
MCFADYEN, IJ
RAAB, G
FORREST, APM
LANGLANDS, AO
STEWART, HJ
ROBERTS, MM
HAMILTON, T
GOLDER, MP
GROOM, GV
GRIFFITHS, K
CLINICAL ONCOLOGY, 1979, 5 (03): : 251 - 256
[25] Cost-utility analysis of anastrozole versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer (EBC): A UK National Health Service (NHS) perspective
Brown, R
Benedict, A
Mansel, RE
VALUE IN HEALTH, 2004, 7 (06) : 670 - 670
[26] Comparison of the cost-effectiveness of upfront letrozole or anastrozole, or switched exemestane versus tamoxifen for early breast cancer in hormone receptor positive (HR+) postmenopausal women: the UK perspective
Di Trapani, F.
Karnon, J.
Kaura, S.
EJC SUPPLEMENTS, 2007, 5 (04): : 202 - 203
[27] A cost-effectiveness analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with early-stage breast cancer in Mexico
Mould-Quevedo, J.
Tapia-Valencia, J.
Davila-Loaiza, G.
VALUE IN HEALTH, 2007, 10 (03) : A124 - A125
[28] Cost-effectiveness analysis of extended adjuvant endocrine therapy in the treatment of post-menopausal women with hormone receptor positive breast cancer
Aysegul Erman
Arlene Nugent
Eitan Amir
Peter C. Coyte
Breast Cancer Research and Treatment, 2014, 145 : 267 - 279
[29] Cost-effectiveness analysis of extended adjuvant endocrine therapy in the treatment of post-menopausal women with hormone receptor positive breast cancer
Erman, Aysegul
Nugent, Arlene
Amir, Eitan
Coyte, Peter C.
BREAST CANCER RESEARCH AND TREATMENT, 2014, 145 (02) : 267 - 279
[30] Obesity and outcome of post-menopausal women receiving adjuvant letrozole for breast cancer
Zekri, Jamal
Farag, Kamel
Allithy, Ahmed
ECANCERMEDICALSCIENCE, 2018, 12

← 1 2 3 4 5 →